Visionary Leader Derek Maetzold, CEO of Castle Biosciences, Honored as CEO of the Year by The CEO Magazine

In a momentous announcement that resonates across the healthcare and biotechnology sectors, Derek Maetzold, the esteemed Founder, President, and Chief Executive Officer of Castle Biosciences, Inc., has been formally recognized with the prestigious CEO of the Year Award by The CEO Magazine. This highly coveted accolade, unveiled on October 1, 2025, celebrates Maetzold's transformative leadership, pioneering vision, and an unwavering commitment to revolutionizing personalized medicine, particularly within the critical field of cancer diagnostics.

Under Maetzold's astute guidance, Castle Biosciences (NASDAQ: CSTL) has not merely carved out a niche but has solidified its position as a vanguard in the diagnostics industry.

The company stands at the forefront of delivering personalized genomic information, empowering clinicians and patients alike with actionable insights that profoundly improve cancer treatment decisions. This award serves as a powerful testament to Maetzold's strategic foresight and his relentless pursuit of excellence, which have collectively propelled Castle Biosciences to new heights of innovation and patient impact.

The CEO Magazine highlighted Maetzold’s exceptional entrepreneurial spirit and his pivotal role in fostering a culture of innovation that drives the development and commercialization of advanced diagnostic tests.

These groundbreaking tests provide crucial prognostic information for various challenging skin cancers, including melanoma and cutaneous squamous cell carcinoma, among others. By transforming complex genomic data into clear, clinically relevant guidance, Castle Biosciences is fundamentally reshaping how these conditions are diagnosed and managed, ultimately leading to improved patient outcomes and more tailored treatment pathways.

Maetzold, in expressing his gratitude, emphasized the collaborative effort behind this recognition.

"I am profoundly honored to receive this recognition, which I believe truly reflects the tireless hard work, dedication, and ingenuity of the entire Castle Biosciences team," he stated. "Our foundational mission has always been to equip clinicians and patients with the most critical and comprehensive information possible, enabling them to make more informed and effective treatment decisions.

This award stands as a powerful validation of our collective efforts and reinforces our commitment to pushing the boundaries of what's possible in personalized medicine."

This recognition from The CEO Magazine not only underscores Maetzold's individual achievements but also shines a spotlight on Castle Biosciences' broader dedication to scientific advancement and patient advocacy.

It heralds a future where genomic insights continue to play an increasingly vital role in healthcare, offering hope and precision in the fight against cancer. Maetzold's leadership continues to inspire, promising further breakthroughs and a continued commitment to enhancing the lives of patients worldwide through innovative diagnostic solutions.